Mixing and Matching Drugs: What Makes Sense?

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 657-664

  Welzel, Tania M ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Directly acting antiviral combination agents; Hepatitis C; Interferon free treatment

Indexed keywords

BOCEPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

COMBINATION CHEMOTHERAPY; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; REVIEW; TREATMENT RESPONSE; VIRAL GENETICS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80051931995     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.012     Document Type: Review

References (24)

1. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE Study. AASLD 2010, [abstract: LB-2].
2. Bronowicki J., McCone J., Bacon B.R., et al. Response-guided therapy (RGT) with boceprevir (BOC) + peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis C virus (HCV) genotype (G) 1 was similar to a 48-wk fixed-duration regimen with BOC+P/R in SPRINT-2. AASLD 2010, [abstract: LB-15].
3. Poordad F., McCone J., Bacon B.R., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. N Engl J Med 2011, 54:1195-1206.
4. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for treatment of chronic hepatitis C genotype 1 nonresponders. N Engl J Med 2011, 54:1207-1217.
5. Guidance for industry: chronic hepatitis C virus infection: developing direct-acting antiviral agents for treatment. Draft guidance 2010, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville (MD), p. 1-27. Available at:, Accessed May 19, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM225333.pdf.
6. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
7. Available at: Accessed February 21, 2011. http://www.pharmasset.com/pipeline.
8. Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 2010, 6:e1001005.
9. Olsen D.B., Carroll S.S., Handt L., et al. HCV antiviral activity and resistance analysis in chronically infected chimpanzees treated with NS3/4A protease and NS513 polymerase inhibitors. J Hepatol 2007, 46:S298.
10. Gane E.J., Roberts S.K., Stedman C.A., et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010, 376:1467-1475.
11. Zeuzem S., Asselah T., Angus P., et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial. AASLD 2010, [abstract: LB-7].
12. Zeuzem S., Buggisch P., Agarwal K., et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment naïve, genotype 1 HCV subjects. AASLD 2010, [abstract: LB-1].
13. Available at: Accessed February 21, 2011. http://www.vrtx.com/current-projects/drug-candidates/vx-222.html.
14. Available at: Accessed February 21, 2011. http://www.abbott.com/global/url/pressRelease/en_US/Press_Release_0824.htm.
15. Lok A., Gardiner D.F., Lawitz E., et al. Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA through 12 weeks of therapy in HCV genotype 1 null responders. AASLD 2010, [abstract: LB-8].
16. Available at: Accessed February 21, 2011. http://www.pharmasset.com/pipeline/psi_7851.aspx.
17. Available at: Accessed February 21, 2011. http://www.natap.org/2010/HCV/011111_01.htm.
18. Available at: Accessed February 21, 2011. http://www.pharmasset.com/pipeline/psi_938_psi_879.aspx.
19. Flisiak R., Feinman S.V., Jablkowski M., et al. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009, 49:1460-1468.
20. Flisiak R., Horban A., Gallay P., et al. The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus. Hepatology 2008, 47:817-826.
21. Coelmont L., Kaptein S., Paeshuyse J., et al. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Antimicrob Agents Chemother 2009, 53:967-976.
22. Hofmann W.P., Herrmann E., Sarrazin C., et al. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int 2008, 28:1332-1343.
23. Dixit N.M., Layden-Almer J.E., Layden T.J., et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924.
24. Hézode C., Forestier N., Dusheiko G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.